Colonic and Anorectal Manifestations of Systemic Sclerosis
Purpose of Review
Systemic sclerosis is a chronic autoimmune disorder commonly involving the gastrointestinal tract, including the colon and anorectum. In this review, we summarize major clinical manifestations and highlight recent developments in physiology, diagnostics, and treatment.
The exact pathophysiology of systemic sclerosis is unclear and likely multifactorial. The role of the microbiome on gastrointestinal manifestations has led to a better understanding of potential pathogenic gut flora. Carbohydrate malabsorption is common. Evaluation using fecal calprotectin and high-resolution anorectal manometry may broaden our understanding of the etiologies of diarrhea and fecal incontinence and help with early recognition of pathology. Prucalopride, a high-affinity 5HT4 agonist, and pyridostigmine, an acetylcholinesterase inhibitor, may help improve colonic transit in patients with constipation. Intravenous immunoglobulins have been used to target muscarinic receptor antibodies that are believed to contribute to gastrointestinal dysmotility.
Colonic and anorectal manifestations of systemic sclerosis include constipation, diarrhea, and fecal incontinence, and can diminish quality of life for these patients. Recent studies regarding pathophysiology as well as diagnostic and treatment options are promising. Further targeted studies to facilitate early intervention and better management of refractory symptoms are still needed.
KeywordsConstipation Diarrhea Fecal incontinence Anorectal Scleroderma Systemic sclerosis
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 17.• Vigone B, Caronni M, Severino A, Bellocchi C, Baldassarri AR, Fraquelli M, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017;19(1):145. Pivotal study examining prucalopride as a treatment option in systemic sclerosis patients. CrossRefGoogle Scholar
- 23.• Smith E, Pauling JD. The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: a systematic literature review. Semin Arthitis Rheum. 2018. Comprehensive review of the evidence regarding dietary modification for gastrointestinal symptoms in systemic sclerosis. Google Scholar
- 26.• Gomes JP, Santos L, Shoenfeld Y. Intravenous immunoglobulin (IVIG) in the vanguard therapy of systemic sclerosis. Clin Immunol. 2018. Current review regarding IVIG use in systemic sclerosis. Google Scholar
- 38.Richard N, Hudson M, Gyger G, et al. Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology (Oxford). 2017;56(4):581–8.Google Scholar
- 48.• Collins J, Mazor Y, Jones M, et al. Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence: a case-control study. Scand J Gastroenterol. 2016;51(12):1433–8. Pivotal study supporting the use of biofeedback for fecal incontinence in systemic sclerosis patients. CrossRefGoogle Scholar